Standard BioTools Inc. (NASDAQ:LAB) Shares Sold by Nikko Asset Management Americas Inc.

Nikko Asset Management Americas Inc. lowered its position in shares of Standard BioTools Inc. (NASDAQ:LAB) by 30.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 6,618,394 shares of the company’s stock after selling 2,954,098 shares during the quarter. Nikko Asset Management Americas Inc.’s holdings in Standard BioTools were worth $11,516,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in Standard BioTools by 7.7% during the third quarter. JPMorgan Chase & Co. now owns 139,748 shares of the company’s stock valued at $270,000 after buying an additional 9,995 shares in the last quarter. HighTower Advisors LLC raised its stake in Standard BioTools by 13.0% during the fourth quarter. HighTower Advisors LLC now owns 92,791 shares of the company’s stock valued at $162,000 after buying an additional 10,690 shares in the last quarter. Wolverine Trading LLC acquired a new stake in Standard BioTools during the third quarter valued at approximately $27,000. Cibc World Markets Corp acquired a new stake in Standard BioTools during the fourth quarter valued at approximately $48,000. Finally, Simon Quick Advisors LLC acquired a new stake in shares of Standard BioTools during the 4th quarter worth approximately $54,000. Institutional investors and hedge funds own 53.74% of the company’s stock.

Insider Transactions at Standard BioTools

In other Standard BioTools news, Director Casdin Partners Master Fund, L bought 4,820,959 shares of the stock in a transaction that occurred on Friday, February 28th. The shares were purchased at an average cost of $1.06 per share, for a total transaction of $5,110,216.54. Following the transaction, the director now directly owns 58,846,780 shares in the company, valued at $62,377,586.80. The trade was a 8.92 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 53.10% of the company’s stock.

Standard BioTools Trading Up 3.6 %

Shares of Standard BioTools stock opened at $1.14 on Monday. The business’s 50 day simple moving average is $1.46 and its 200-day simple moving average is $1.74. The stock has a market capitalization of $432.04 million, a price-to-earnings ratio of -1.61 and a beta of 1.62. Standard BioTools Inc. has a twelve month low of $0.99 and a twelve month high of $3.04.

Analysts Set New Price Targets

Separately, KeyCorp cut Standard BioTools from an “overweight” rating to a “sector weight” rating in a research report on Thursday, February 27th.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.